fda changes tirzepatide 🚨 Moves to Permanently Shut Down Compounded GLP-1s The FDA is taking steps to eliminate large-scale compounding of GLP-1 medications like semaglutide and tirzepatide, signaling a major shift in how these FDA sets tirzepatide compounding deadlines

Int J Clin Pharmacol Ther 45(2):114120 le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L et al (2017) 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

However, coverage for GLP-1 medications used to treat diabetes will continue

10.1677/erc.1.01150 Endocr

In contrast, resmetirom reduced fat mass, but not lean mass

Unfortunately, there was no comparison with an 'in person' visit, as likely their conclusions would then be a bit more objective ("Nevertheless, while direct-to-consumer platforms have increased patient access to GLP-1 RAs, these findings suggest that some do so through impersonal care that prioritizes quick prescriptions over comprehensive care")

Always consult with a qualified healthcare provider before starting any peptide regimen